Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials

被引：0
|
作者：
Gooderham, Melinda [1 ]
Elewski, Boni [2 ]
Pariser, David [3 ,4 ]
Sofen, Howard [5 ]
Mendelsohn, Alan [6 ]
Cichanowitz, Nicole [7 ]
Li, Qing [7 ]
la Rosa, Carmen [7 ]
机构：
[1] Prob Med Res & Skin Ctr Dermatol, Peterborough, ON, Canada
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[3] Eastern Virginia Med Sch, Williamsburg, VA USA
[4] Virginia Clinical Res Inc, Norfolk, VA USA
[5] Univ Calif Los Angeles, Dept Med Dermatol, Los Angeles, CA 90024 USA
[6] Sun Pharmaceut, Philadelphia, PA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
7092
引用
收藏
页码：AB166 / AB166
页数：1
相关论文
共 50 条
  • [41] Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
    Genovese, Mark C.
    Colombel, Jean-Frederic
    Gellett, Amanda M.
    Xu, Wen
    Hardin, Dana
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [42] Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials
    Gordon, K
    Pariser, D
    Langley, R
    Caro, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P1 - P1
  • [43] Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Reich, Kristian
    Deodhar, Atul A.
    McInnes, Iain B.
    Porter, Brian
    Das Gupta, Ayan
    Pricop, Luminita
    Fox, Todd
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (04) : 473 - 479
  • [44] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P.
    Kerdel, F.
    Gu, Y.
    Valdes, J. M.
    Thompson, E. H.
    Lynde, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
  • [45] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P-D
    Kerdel, F.
    Gu, Y.
    Valdes, J.
    Thompson, E. H.
    Lynde, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 115 - 116
  • [46] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [47] POPULATION PHARMACOKINETICS OF RISANKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: ANALYSES INCLUDING THE DATA FROM PHASE III CLINICAL TRIALS.
    Suleiman, A. A.
    Khatri, A.
    Minocha, M.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S44 - S44
  • [48] Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
    Lasa, J. S.
    Sambuelli, A.
    Zubiaurre, I.
    Correa, G. J.
    Lubrano, P.
    Balderramo, D. C.
    Ruffinengo, O.
    Brion, L.
    Leonardi, D. B.
    El-Iakeh, J.
    Guimaraens, P. N.
    Olivera Sendra, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S546 - S547
  • [49] Psychometric properties of the itch numeric rating scale in patients with moderate to severe plaque psoriasis using data from a randomized clinical trial
    Naegli, April
    Zhu, Baojin
    Gaich, Carol
    Heredia, Emily
    Song, Grace
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB181 - AB181
  • [50] Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
    Egeberg, Alexander
    Jullien, Denis
    Du Jardin, Kristian Gaarn
    Thaci, Diamant
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
12345